2-(2,5-dichloro-pyrimidin-4-ylamino)-N-ethyl-benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2,5-dichloro-pyrimidin-4-ylamino)-N-ethyl-benzamide
• 英文别名: 2-[(2,5-dichloropyrimidin-4-yl)amino]-N-ethylbenzamide
• 化学式: C₁₃H₁₂Cl₂N₄O
• 分子量: 311.17
• InChiKey: ALNPXJKDQKRBSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  66.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4-Amino-2-chloro-phenyl)-2-morpholin-4-yl-acetamide 、 2-(2,5-dichloro-pyrimidin-4-ylamino)-N-ethyl-benzamide 在 三氟乙酸 作用下， 以 仲丁醇 为溶剂， 反应 12.0h， 生成 N-ethyl-2-[-[5-chloro-2-[4-((morpholin-4-yl)acetamido)-3-chloroanilino]pyrimidin-4-yl]amino]benzamide
  参考文献：
  名称：

  Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines

  摘要：

  A new class of pyrimidine derivatives were designed and synthesized as potential dual FAK and EGFR(T79)(0M) inhibitors using a fragment-based drug design strategy. This effort led to the identification of the two most active inhibitors, namely 9a and 9f, against both FAK (IC50, = 1.03 and 3.05 nM, respectively) and EGFR(T79)(0M) (IC50 = 3.89 and 7.13 nM, respectively) kinase activity. Moreover, most of these compounds also exhibited strong antiproliferative activity against the three evaluated FAK-overexpressing pancreatic cancer (PC) cells (AsPC-1, BxPC-3, Panc-1) and two drug-resistant cancer cell lines (breast cancer MCF-7/adr cells and lung cancer H1975 cells) at concentrations lower than 6.936 mu M. In addition, 9a was also effective in the in vivo assessment conducted in a FAK-driven human AsPC-1 cell xenograft mouse model. Overall, this study offers a new insight into the treatment of hard to treat cancers.

  DOI：

  10.1016/j.bioorg.2019.103408
• 作为产物：
  描述：

  邻硝基苯甲酸 在 甲醇 、 氯化亚砜 、 铁粉 、 氯化铵 、 N,N-二异丙基乙胺 作用下， 以 水 、 异丙醇 为溶剂， 反应 13.0h， 生成 2-(2,5-dichloro-pyrimidin-4-ylamino)-N-ethyl-benzamide
  参考文献：
  名称：

  Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines

  摘要：

  A new class of pyrimidine derivatives were designed and synthesized as potential dual FAK and EGFR(T79)(0M) inhibitors using a fragment-based drug design strategy. This effort led to the identification of the two most active inhibitors, namely 9a and 9f, against both FAK (IC50, = 1.03 and 3.05 nM, respectively) and EGFR(T79)(0M) (IC50 = 3.89 and 7.13 nM, respectively) kinase activity. Moreover, most of these compounds also exhibited strong antiproliferative activity against the three evaluated FAK-overexpressing pancreatic cancer (PC) cells (AsPC-1, BxPC-3, Panc-1) and two drug-resistant cancer cell lines (breast cancer MCF-7/adr cells and lung cancer H1975 cells) at concentrations lower than 6.936 mu M. In addition, 9a was also effective in the in vivo assessment conducted in a FAK-driven human AsPC-1 cell xenograft mouse model. Overall, this study offers a new insight into the treatment of hard to treat cancers.

  DOI：

  10.1016/j.bioorg.2019.103408

文献信息

• ANTHRANILAMIDE INHIBITORS OF AURORA KINASE
  申请人：Johnson Neil W.

  公开号：US20080182852A1

  公开（公告）日：2008-07-31

  The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof; where R 1 , R 2 , R 3 , R 4 , r and s are as previously defined. Compounds of the present invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer.

  本发明涉及以下公式所代表的化合物： 或其药学上可接受的盐； 其中R1、R2、R3、R4、r和s如前所定义。本发明的化合物在治疗与Aurora激酶活性相关的疾病，如癌症方面是有用的。
• [EN] 2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS<br/>[FR] 2,4-DI(PHENYLAMINO)PYRIMIDINES UTILISEES POUR TRAITER DES MALADIES NEOPLASIQUES, DES TROUBLES INFLAMMATOIRES ET DES TROUBLES DU SYSTEME IMMUNITAIRE
  申请人：NOVARTIS AG

  公开号：WO2004080980A1

  公开（公告）日：2004-09-23

  Novel pyrimidine derivatives of formula (I), to processes for their production, their use as pharmaceuticals in the treatment of neoplastic diseases, inflammatory and immune system disorders and to pharmaceutical compositions comprising them.

  化合物(I)的新型嘧啶衍生物，其生产方法，它们作为药物在治疗肿瘤性疾病、炎症和免疫系统紊乱中的应用，以及包含它们的药物组合物。
• [EN] 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS<br/>[FR] 2, 4-PYRIMIDINE DIAMINES UTILES DANS LE CADRE DU TRAITEMENT DE MALADIES NEOPLASIQUES, DE TROUBLES INFLAMMATOIRES ET DE TROUBLES DU SYSTEME IMMUNITAIRE
  申请人：NOVARTIS AG

  公开号：WO2005016894A1

  公开（公告）日：2005-02-24

  Novel pyrimidine derivatives of formula (I) Wherein R is selected from C16-10 aryl, C5-10heteroaryl, C3-12cycloalkyl and C3-10heterocycloalkyl; R0-R6 as described herein; and their use for the manufacture of a medicament for the treatment or prevention of a disease wich responds to inhibition of FAK and/or ALK and/or ZAP-70 and/or IGF-IR.

  化合物式(I)中的新型嘧啶衍生物，其中R从C16-10芳基，C5-10杂芳基，C3-12环烷基和C3-10杂环烷基中选择；R0-R6如此处所述；以及它们的用途，制造用于治疗或预防对FAK和/或ALK和/或ZAP-70和/或IGF-IR抑制有反应的疾病的药物。
• 2,4-Di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
  申请人：Garcia-Echeverria Carlos

  公开号：US20060247241A1

  公开（公告）日：2006-11-02

  Novel pyrimidine derivatives of formula I to process for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them

  式I的新型嘧啶衍生物的制备方法，其用途作为药物以及包含它们的药物组合物的制备方法。
• FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
  申请人：Ahmed Gulzar

  公开号：US20090221555A1

  公开（公告）日：2009-09-03

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供公式I或II化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。公式I或II化合物具有ALK和/或c-Met抑制活性，可用于治疗增殖性疾病。